UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000002471
Receipt number R000003028
Scientific Title The study of specific protein markers in pineal parenchymal tumors
Date of disclosure of the study information 2009/09/08
Last modified on 2019/03/18 06:56:21

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The study of specific protein markers in pineal parenchymal tumors

Acronym

Pineal parenchymal tumors

Scientific Title

The study of specific protein markers in pineal parenchymal tumors

Scientific Title:Acronym

Pineal parenchymal tumors

Region

Japan


Condition

Condition

Pineal parenchymal cell tumors

Classification by specialty

Neurosurgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

We analyze pineal parenchymal tumors and embryonal tumors in CNS by immunohistochemistry for evidence of melatonin synthesis.

Basic objectives2

Others

Basic objectives -Others

We will make the antibody against hydroxyindol-O-methyltransferase (HIOMT) and analyze normal pineal glands and the other human organs by immunohistochemistry for evidence of melatonin synthesis. We will further analyze the correlation of the expression of HIOMT with the histological differentiation of PPTs.

Trial characteristics_1

Confirmatory

Trial characteristics_2

Explanatory

Developmental phase

Not applicable


Assessment

Primary outcomes

Control tissue, consisting of cerebrum, cerebellum, brain stem, spinal cord, dorsal root ganglion, pineal gland, pituitary gland, thyroid gland, parathyroid gland, adrenal gland, lung, heart, liver, spleen, pancreas, stomach, duodenum, small intestine, colon, kidney, prostate, testis, ovary, and bone marrow, was obtained from patients without neurologic disease and without pathologic abnormalities. Tumor specimens consisted of 8 PPTs (one PC, four PPTIDs, three PB), 3 central nervous system primitive neuroectodermal tumors (PNET), and 8 medulloblastomas (MB). We analyze normal pineal glands, the other human organs, PPTs, and embryonal tumors in CNS by immunohistochemistry for evidence of melatonin synthesis. We further analyse the correlation of the expression of HIOMT with the histological differentiation of PPTs.

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

0 years-old <=

Age-upper limit

100 years-old >=

Gender

Male and Female

Key inclusion criteria

The cases of pineal parenchymal tumor
The cases of PNET
The cases of medulloblastoma
The cases without neurologic disease and without pathologic abnormalities

Key exclusion criteria

The cases with neurologic disease and without pathologic abnormalities

Target sample size

80


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Takahiro Fukuda

Organization

Research Center for Medical Science, The Jikei University School of Medicine

Division name

Division of Neuropathology, Department of Neurosciences

Zip code


Address

3-25-8 Nishi-shimbashi, Minato-ku, Tokyo

TEL

03-3433-1111

Email



Public contact

Name of contact person

1st name
Middle name
Last name Takahiro Fukuda

Organization

Research Center for Medical Science, The Jikei University School of Medicine

Division name

Division of Neuropathology, Department of Neurosciences

Zip code


Address

3-25-8 Nishi-shimbashi, Minato-ku, Tokyo

TEL

03-3433-1111

Homepage URL


Email

fukuda-t@jikei.ac.jp


Sponsor or person

Institute

Division of Neuropathology, Department of Neurosciences, Research Center for Medical Science, The Jikei University School of Medicine

Institute

Department

Personal name



Funding Source

Organization

Division of Neuropathology, Department of Neurosciences, Research Center for Medical Science, The Jikei University School of Medicine

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

YES

Study ID_1

20-201 5491

Org. issuing International ID_1

The Jikei University School of Medicine

Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

東京慈恵会医科大学


Other administrative information

Date of disclosure of the study information

2009 Year 09 Month 08 Day


Related information

URL releasing protocol


Publication of results

Partially published


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results

In human tissue, HIOMT was expressed in retinal cells, pineal parenchymal cells, neurons of the Edinger-Westphal nucleus, microglia, macrophages, thyroid follicular epithelium, principal and oxyphil cells of parathyroid gland, adrenal cortical cells, hepatic parenchymal cells, renal tubule epithelial cells, and enteroendocrine cells of stomach and duodenum. HIOMT was expressed in all PPTs studied. The ratio of HIOMT-immunoreactive cells successively decreased in the following tumors: pineocytoma, pineocytomatous area of PPTIDs, PPTID, pineoblastomatous area of PPTIDs, and pineoblastoma. In one of three PNETs and four of eight MBs, a few HIOMT-immunoreactive cells were observed. HIOMT immunohistochemistry is useful in diagnosing PPTs and may be one of the predictive factors affecting the survival of PPTs.

Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2009 Year 02 Month 01 Day

Date of IRB

2009 Year 01 Month 09 Day

Anticipated trial start date

2009 Year 02 Month 01 Day

Last follow-up date

2011 Year 01 Month 01 Day

Date of closure to data entry

2011 Year 01 Month 01 Day

Date trial data considered complete


Date analysis concluded



Other

Other related information

Sampling by case control


Management information

Registered date

2009 Year 09 Month 08 Day

Last modified on

2019 Year 03 Month 18 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000003028


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name